title: Revisiting the cost-effectiveness of omalizumab.
authors.forename: J D
authors.initials: JD
authors.lastname: Campbell
authors.forename: D E
authors.initials: DE
authors.lastname: Spackman
authors.forename: S D
authors.initials: SD
authors.lastname: Sullivan
mesh_terms: D018927:Anti-Asthmatic Agents / Q000191:economics* / Q000627:therapeutic use; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000188:drug therapy* / Q000191:economics; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D006801:Humans; D018803:Models, Economic; D000069444:Omalizumab
chemical_list: D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab